National Cancer Institute National Cancer Institute
U.S. National Institutes of Health National Cancer Institute
NCI Home Cancer Topics Clinical Trials Cancer Statistics Research & Funding News About NCI

Clinical Trial Results

Summaries of Newsworthy Clinical Trial Results

< Back to Main

    Posted: 07/23/2009
Page Options
Print This Page  Print This Page
E-Mail This Document  E-Mail This Document
Browse by Cancer Type
Breast Cancer

Lung Cancer

Prostate Cancer

More Results
Search Trial Results

    Search  
Quick Links
Director's Corner

Dictionary of Cancer Terms

NCI Drug Dictionary

Funding Opportunities

NCI Publications

Advisory Boards and Groups

Science Serving People

Español
NCI Highlights
Restructuring the NCI Clinical Trials Enterprise

Clinical Trials Reporting Program

Coordinating Center for Clinical Trials

States Requiring Coverage of Clinical Trial Costs
Related Pages
Search for Clinical Trials
NCI's PDQ® Cancer Clinical Trials Registry.

Leukemia Home Page
NCI's gateway for information about leukemia.
For Children with Leukemia, Radiation May Be Unnecessary

Adapted from the NCI Cancer Bulletin, vol. 6/no. 13, June 30, 2009 (see the current issue).

Children with the most common form of leukemia can safely forego radiation therapy to prevent a relapse of the disease if they are treated with chemotherapy regimens tailored to their individual needs. This is the conclusion of a clinical trial involving 498 patients with acute lymphoblastic leukemia (ALL). Nearly 94 percent of the patients were still alive 5 years after treatment, a result that compares favorably with other ALL treatment studies.

The strategies and treatments employed in this trial could be adopted by other medical centers, said researchers from St. Jude Children's Research Hospital in Memphis, who published their results in the June 25, 2009, issue of the New England Journal of Medicine (see the journal abstract).

Cranial irradiation has been used since the 1960s as a way to prevent a recurrence of cancer in the brain. First introduced by researchers at St. Jude, it was considered a breakthrough and improved survival rates in the disease to about 50 percent. Thanks to continued improvements in chemotherapy, today 90 percent of children with ALL are cured of their disease.

But with a growing population of survivors and clear evidence that radiation exposure can lead to second cancers and cognitive problems, many centers have limited its use to patients at risk of a relapse. In the trial, Ching-Hon Pui, M.D., and his colleagues tailored chemotherapy regimens for each patient and used the latest techniques for delivering the drugs and monitoring their effectiveness. After several weeks, adjustments could be made if a patient had evidence of residual cancer cells.

Based in part on comparisons with historical data on patients with ALL, the researchers conclude that individualized chemotherapy regimens are preferred over treatments that include cranial irradiation. They even recommend against irradiation for patients considered at risk of relapse. If this group had received radiation therapy in the current study, the researchers explained, 90 percent of the patients would have received radiation unnecessarily.

"The introduction of radiation therapy in the 1960s put the word 'cure' into discussions of ALL," said coauthor and director of St. Jude, William Evans, Pharm.D. "The importance of the current study is that we're now removing radiation from the therapy. And the reason we're able to do this is that we've gotten smarter and better at using chemotherapy."

Back to TopBack to Top


A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov